The PI3K/Akt/mTOR pathway is primarily activated at different targets in diseases with BRAF and RAS mutations, and these specific combinations have been shown to induce thyroid cancer progression in mouse models [42]. This evidence concerns the gene BRAF and thyroid gland carcinoma.